TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

Volver

Resultados 90 resultados LastUpdate Última actualización 20/04/2018 [18:13:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



previousPage Página2 de 4 nextPage   Mostrar por página


METHOD FOR THE RISK OF FORMING CHRONIC HEART FAILURE EVALUATING IN YOUNG MEN, SUFFERING FROM ARTERIAL HYPERTENSION

NºPublicación: RU2649497C1 03/04/2018

Solicitante:
FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE OBRAZOVATELNOE UCHREZHDENIE VYSSHEGO OBRAZOVANIYA SARATOVSKIJ [RU]

Resumen de: RU2649497C1

FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to cardiology and can be used to assess the risk of chronic heart failure in young men with arterial hypertension. Determining the cardiotrophin-1 plasma concentration. Determining the ratio of the maximum velocities of the transmittal blood flow at the beginning and end of the diastole (E/A) initially and at the height of hyperglycemia when an intravenous load by an individual standardized dose of glucose is administered. Calculating the value of the glucose-induced change in E/A as the modulus of the E/A difference, defined initially and at the height of hyperglycemia. If the value of the glucose-induced change in E/A is greater than or equal to 0.5, 1 point is awarded, less than 0.5 is 0 points. With a cardiotrophin-1 plasma concentration greater than or equal to 200 pg/ml, 1 point is awarded, less than 200 pg/ml 0 points are awarded. Summarizing the points. With a score of 2, a high risk of chronic heart failure developing is predicted. With a score of 1, a moderate risk of chronic heart failure developing is predicted. With a score of 0, a low risk of chronic heart failure developing is predicted.EFFECT: method makes it possible to predict the chronic heart failure formation in young men, suffering from arterial hypertension due to the evaluation of the most significant indicators.1 cl, 2 ex



traducir


 

METHOD FOR MANUFACTURING NON-BLEEDING INJECTION NEEDLE HAVING IMMEDIATE HEMOSTATIC CAPABILITY

NºPublicación: WO2018056737A1 29/03/2018

Solicitante:
KOREA ADVANCED INST SCI & TECH [KR]
INNOTHERAPY INC [KR]

Resumen de: WO2018056737A1

An injection needle coated with chitosan, in which an oxidized catechol group is introduced into chitosan and crosslinked, according to the present invention, has the ability to immediately suppress bleeding occurring at the time of injection. As such, the present invention is effective for injecting not only patients having low hemostatic ability such as diabetic patients, chemotherapy patients and hemophilia patients, but also for patients showing a blood rejection response and children, and has an effect of immediately suppressing hemorrhage of strong pulsing, blood-rich organs such as a heart.



traducir


 

DRUG DELIVERY SYSTEM AND METHOD

NºPublicación: US2018085525A1 29/03/2018

Solicitante:
PRECIFLEX SA [CH]

Resumen de: US2018085525A1

An insulin delivery system and method for dispensing a measured, user selected, amount of insulin, a derivate thereof, or another substance into an animal via a dosing module and a delivery module. The system includes a reusable dosing module. The reusable dosing module is adapted to extract a set volume of the insulin, a derivate thereof, or another substance and a set volume of the diluent from reservoir(s). The reservoir(s) optionally includes a vial, and transfers the set volume(s) to a single use, manually activated injector reservoir. The reusable injector carrier module is configured to house the single use manually activated injector reservoir and configured to provide a surface to stroke or calm the animal prior to injection.



traducir


 

MEDICINE INJECTION AND DISEASE MANAGEMENT SYSTEMS, DEVICES, AND METHODS

NºPublicación: US2018085532A1 29/03/2018

Solicitante:
BIGFOOT BIOMEDICAL INC [US]

Resumen de: US2018085532A1

One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.



traducir


 

SAFETY WARNING SYSTEM

NºPublicación: US2018085538A1 29/03/2018

Solicitante:
THE QUEEN ELIZABETH HOSPITAL KINGS LYNN NHS FOUND TRUST [GB]

Resumen de: US2018085538A1

A safety warning system for detecting glucose in an arterial monitoring or flush system is disclosed. An example of the system comprises a receptacle configured to receive fluid from a line for connecting to a patient, and an indicator arranged to contact the fluid and configured to provide an indication of whether the fluid comprises glucose. The receptacle comprises a gas release path to enable the fluid to displace gas to contact the indicator.



traducir


 

DETECTING APPARATUS BASED ON IMAGE FOR BLOOD GLUCOSE CONCENTRATION AND METHOD THEREOF

NºPublicación: US2018085035A1 29/03/2018

Solicitante:
NATIONAL APPLIED RES LABORATORIES [TW]

Resumen de: US2018085035A1

The present invention provides a detecting apparatus based on image for detecting blood glucose concentration and method thereof. The detecting apparatus comprising a lighting device, an image capture device, a thermal imager and an operating device. The lighting device including a first wavelength of light source and a second wavelength of light source, configured to illuminate skin. The image capture device disposed above the lighting device, configured to capture a first image and a second image corresponding to the first wavelength of light source and the second wavelength of light source illuminated on the skin respectively. The thermal imager is configured to detect temperature of the skin. The operating device is connected to the lighting device, the image capture device and the thermal imager, configured to calculate blood glucose concentration according to the first image, the second image and the temperature.



traducir


 

LOW DOSE PREFILLED DRUG DELIVERY DEVICE AND METHOD

NºPublicación: US2018085527A1 29/03/2018

Solicitante:
BECTON DICKINSON CO [US]

Resumen de: US2018085527A1

A drug delivery device (100) for administering a low dose of a medicament includes a housing (111) and a drug reservoir (101) disposed in the housing (111). A needle (135) is connected to the drug reservoir (101). A pressure applying member (113) is movably connected to the housing (111) and is movable between first and second positions. The pressure applying member (113) does not apply pressure to the drug reservoir (101) in the first position and applies pressure to the drug reservoir (101) in the second position to dispense medicament stored in the drug reservoir (101). A method of administering a low dose of insulin to simulate a first-phase insulin response of a pancreas is also disclosed.



traducir


 

PERSONALIZING PRESET MEAL SIZES IN INSULIN DELIVERY SYSTEM

NºPublicación: US2018089395A1 29/03/2018

Solicitante:
BIGFOOT BIOMEDICAL INC [US]

Resumen de: US2018089395A1

A method may include displaying at least three icons on a user interface of a mobile device, including a first icon associated with the at least three icons associated with a first carbohydrate level, a second icon associated with the at least three icons associated with a second carbohydrate level, and a third icon associated with the at least three icons associated with a third carbohydrate level. The method may also include receiving a user selection of one of the three icons through the user interface of the mobile device, and determining an insulin bolus level from the user selection. The method may also include communicating the insulin bolus level to an insulin delivery device.



traducir


 

METHOD TO RECALIBRATE CONTINUOUS GLUCOSE MONITORING DATA ON-LINE

NºPublicación: US2018089386A1 29/03/2018

Solicitante:
UNIV DEGLI STUDI DI PADOVA [IT]

Resumen de: US2018089386A1

In a method of recalibrating continuous glucose monitoring data from a user, operable on a digital processor, an indication from the user that the user has taken a meal is received (806). A self-monitored of blood glucose levels from the user (810) at two separate times during a day corresponding to when the user has taken a meal. A glucose signal is received from a continuous glucose monitoring sensor (818) at times corresponding to the two separate times that the user has taken a meal. Two reconstructed blood glucose values based on the glucose signal from the continuous monitoring sensor at times when the at least two self-monitored of blood glucose levels are received from the user. A linear regression is performed (822) using y=ax+b, wherein x corresponds to the two reconstructed blood glucose values and y corresponds to the two self-monitored of blood glucose levels thereby generating an estimation of a and b. A recalibration signal, including the estimation of a and b, is transmitted to the continuous glucose monitoring sensor (824) based on the linear regression.



traducir


 

METHOD FOR MEASURING URINARY APOE CONCENTRATION

NºPublicación: US2018088139A1 29/03/2018

Solicitante:
SYSMEX CORP [JP]

Resumen de: US2018088139A1

Disclosed is a method for assisting diagnosis of risk of progression of diabetic nephropathy, comprising measuring the urinary apolipoprotein E (ApoE) concentration of a patient with diabetic nephropathy showing a urinary albumin/Cr ratio of 30 mg/gCr or more, and determining that the patient has a high risk of progressing diabetic nephropathy when the value of urinary ApoE concentration is equal to or greater than a predetermined threshold value.



traducir


 

OPTICAL GLUCOMETER

NºPublicación: WO2018057598A1 29/03/2018

Solicitante:
FURMAN UNIV [US]

Resumen de: WO2018057598A1

Disclosed herein are devices and methods for detecting blood glucose levels in a subject that involve passively quantifying mid-infrared emissions from the eye of the subject.



traducir


 

INSULIN INJECTOR CAPABLE OF DOSAGE MEASUREMENT USING PHOTOSENSOR

NºPublicación: WO2018056606A1 29/03/2018

Solicitante:
CHOI KYU DONG [KR]

Resumen de: WO2018056606A1

The present invention relates to an insulin injector capable of dosage measurement using a photosensor and to an insulin injector which is capable of dosage measurement using a photosensor and comprises: a drug cartridge (10) which stores insulin and in which a movable piston (11) is provided; an injection driving unit (20) comprising a plunger (23) for compressively driving the piston (11); and a main control unit (40) for controlling the driving of the injection driving unit (20), the insulin injector (100) further comprising: a light reflector (110) installed at the other end of the plunger (23); and a dosage measuring unit (120), which comprises an optical transmission unit (121) for transmitting an optical signal towards the light reflector (110), an optical reception unit (122) for receiving the optical signal reflected by the light reflector (110), and a dosage calculation module (123) for comparing the optical signal transmitted by the optical transmission unit (121) with the optical signal received by the optical reception unit (122) and measuring the linear travel distance of the plunger (23), and which transmits, to the main control unit (40), the linear travel distance of the plunger (23) calculated by the dosage calculation module (123).



traducir


 

AUTOMATED SYSTEM FOR CONTROLLING THE BLOOD GLUCOSE LEVEL OF A PATIENT

NºPublicación: WO2018055284A1 29/03/2018

Solicitante:
COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES [FR]

Resumen de: WO2018055284A1

The invention concerns a blood glucose level control system, comprising: a blood glucose level sensor (101); an insulin injection device (103); and a treatment and control unit (105) predicting the future development of the blood glucose level from a physiological model and consequently controlling the insulin injection device (103), in which the treatment and control unit (105) is suitable for: a) implementing a calibration of the model, taking into account a measured blood glucose level history; b) after the calibration step, determining if the model is satisfactory from at least one digital indicator representative of the discrepancy between the blood glucose level estimated from the model and the actual blood glucose level measured by the sensor (101); and c) if the quality of the model is not satisfactory, controlling the insulin injection device (103) without taking into account the predictions made from the model.



traducir


 

MEDICAL DEVICE FOR THE EARLY DIAGNOSIS OF METABOLIC DISEASES

NºPublicación: WO2018055568A1 29/03/2018

Solicitante:
INST POLITECNICO DE LEIRIA [PT]

Resumen de: WO2018055568A1

The present invention relates to a medical device for the early diagnosis of metabolic diseases that is used to determine the function of the carotid bodies, in a non-invasive manner, associating the function of these organs with the metabolic functions of the body, specifically the production of insulin and the absorption of glucose, and also the measurement of sympathetic tone. This device is suitable for diagnosing alterations in the function of the carotid bodies in individuals who are overweight and who have a family history of metabolic disease, essential arterial hypertension and dyslipidemia. The device comprises a thoracoabdominal sensor unit with an elastic abdominal band (9) and a chest band (10), a transcutaneous partial oxygen pressure sensor (3), and a naso-auricular sensor unit positioned on the earlobe. The device also has temperature sensors (8), continuous glucose measurement sensors (7), movement sensors (4), a transcutaneous partial oxygen pressure sensor (3), a peripheral oxygen saturation sensor (1) and three electrodes for acquiring electrocardiogram line tracings, which are linked to the acquisition and recording module (5), which includes a push button (6).



traducir


 

METHOD AND APPARATUS FOR ASSISTING DIAGNOSIS OF RISK OF PROGRESSION OF DIABETIC NEPHROPATHY

NºPublicación: EP3299820A1 28/03/2018

Solicitante:
SYSMEX CORP [JP]

Resumen de: EP3299820A1

Disclosed is a method for assisting diagnosis of risk of progression of diabetic nephropathy, comprising measuring urinary apolipoprotein E (ApoE) concentration of a patient with diabetic nephropathy showing a urinary albumin/Cr ratio of 30 mg/gCr or more, and determining that the patient has a high risk of progressing diabetic nephropathy when the value of urinary ApoE concentration is equal to or greater than a predetermined threshold value.



traducir


 

SIMULATION MODEL OF TYPE 1 DIABETIC PATIENT DECISION-MAKING

NºPublicación: EP3298520A1 28/03/2018

Solicitante:
DEXCOM INC [US]

Resumen de: WO2016187321A1

A mathematical model of type I diabetes (T1D) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. insulin dosing) driven by either self-monitoring blood glucose (SMBG) or continuous glucose monitoring (COM). The decision-making (DM) model can simulate real-life situations and everyday patient behaviors. Accurate submodels of SMBG and COM measurement errors are incorporated in the comprehensive DM model. The DM model accounts for common errors the patients are used to doing in their diabetes management, such as miscalculations of meal carbohydrate content, early/delayed insulin administrations and missed insulin boluses. The DM model can be used to assess in silico if/when CGM can safely substitute SMBG in T1D management, to develop and test guidelines for CGM driven insulin dosing, to optimize and individualize off-line insulin therapies and to develop and test decision support systems.



traducir


 

NOVEL FORMULATIONS

NºPublicación: US2018078645A1 22/03/2018

Solicitante:
ARECOR LTD [GB]

Resumen de: US2018078645A1

According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue, ionic zinc, a chelating agent and polysorbate 80.



traducir


 

IMPLANTABLE INTESTINAL REACTOR

NºPublicación: US2018078746A1 22/03/2018

Solicitante:
UNIV GRENOBLE ALPES [FR]
CENTRE HOSPITALIER UNIV GRENOBLE [FR]

Resumen de: US2018078746A1

The device, that can be implanted in the intestinal cavity, comprises a reactor comprising a semi-permeable or porous membrane or coating linked to a element for attachment to an intestinal or gastric wall. The reactor can be in the form of a ribbon, a structure having more than two faces or an open structure delimiting a lumen, comprising, or formed from, a semi-permeable or porous membrane. The reactor can also delimit, at least partially with the semi-permeable or porous membrane of same, a closed inner space. The reactor can comprise or carry enzymes or micro-organisms, in particular bacteria or yeast. The reactor is used for generating a chemical reaction with one or more molecules present in the intestine, or for producing one or more biologically active molecules. It can, in particular, be used for consuming sugars, disaccharides and simple sugars or producing essential amino acids or other molecules having a positive effect on the health.



traducir


 

METHOD OF DIAGNOSTICS OF LIVER STEATOSIS

NºPublicación: RU2648183C1 22/03/2018

Solicitante:
FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE OBRAZOVATELNOE UCHREZHDENIE VYSSHEGO OBRAZOVANIYA SMOLENSKIJ [RU]

Resumen de: RU2648183C1

FIELD: medicine.SUBSTANCE: invention relates to medicine and can be used to diagnose hepatic steatosis. Height, weight, body mass index of a patient are measured. Presence of diabetes mellitus (DM), arterial hypertension (AH), metabolic syndrome (MS), alcoholic liver disease (ALD) is checked. Fact and timing of taking systemic glucocorticosteroids is clarified. Blood levels of glycated hemoglobin (HbA1c), alanine aminotransferase (ALT), aspartate aminotransferase (ACT), gamma-glutamyltranspeptidase (GGT), alkaline phosphatase (APh), total bilirubin, direct bilirubin and cholesterol are determined. Then, ultrasound inspection of the liver is performed and the ultrasonic wave attenuation factor is determined (dB/cm). Received data are evaluated in points. Liver steatosis is determined by the sum of the points: 0 points - no steatosis; 1-3 points - minimal liver steatosis; 4-9 points - moderate liver steatosis; more than 10 points - pronounced liver steatosis.EFFECT: method allows to accurately and non-invasively conduct a diagnostics of liver steatosis by evaluating the complex of the most significant indicators.1 cl, 1 tbl, 4 ex



traducir


 

INSULIN PEN

NºPublicación: WO2018050955A1 22/03/2018

Solicitante:
OY FISECA LTD

Resumen de: WO2018050955A1

The invention relates to an insulin pen comprising an insulin reservoir (1) and an injection needle (2), and at the opposite end of the insulin pen, a press-button (3), by means of which an insulin dose is injected into the patient's body. The insulin pen comprises a pressure reservoir (4) which is filled with propellant gas and can be opened by pressing the press-button so that the propellant gas presses an insulin dose through the injection needle (2) into the patient's body.



traducir


 

Sharing continuous glucose data and reports

NºPublicación: AU2016346772A1 22/03/2018

Solicitante:
DEXCOM INC

Resumen de: AU2016346772A1

In some example embodiments, there is provided a method, which includes sending a message to a server, wherein the message includes a request for a share code to enable another user to access, via a first computer, analyte data obtained from a host-patient associated with a receiver and/or an analyte report for the host-patient associated with the receiver; receiving, in response to the sending, the share code generated by the server, wherein the share code comprises a checksum portion, a password portion, and an identifier portion indicative of the host-patient; generating a user interface view including the share code; and displaying the user interface view including the share code, wherein the share code enables the other user to access, via the first computer, the analyte data and/or the analyte report. Related systems, methods, and articles of manufacture are also disclosed.



traducir


 

RAPID ESTABLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STEADY-STATE DRUG DELIVERY

NºPublicación: AU2018201551A1 22/03/2018

Solicitante:
INTARCIA THERAPEUTICS INC

Resumen de: AU2018201551A1

The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.



traducir


 

ADJUSTABLE HEIGHT NEEDLE INFUSION DEVICE

NºPublicación: EP3295978A1 21/03/2018

Solicitante:
BECTON DICKINSON CO [US]

Resumen de: EP3295978A1

An infusion set has a retraction dial that can be removably assembled with the infusion set and access a threaded needle hub contained therein such that the dial can be used to advance or retract a needle hub and an inserted needle to a more precisely controlled insertion depth to deliver insulin or other medicament intradermally (i.e. to the upper 3 mm of skin surface). Position of the inserted needle can be maintained by providing a separated and isolated needle hub, main base and main hub of the infusion set that can isolate the inserted needle from external forces such that the needle can be maintained at a depth to deliver content to the upper 3 mm of skin surface during normal use.



traducir


 

METHOD OF MEASURING A BLOOD GLUCOSE BASED ON A RATE OF CHANGE OF BLOOD GLUCOSE LEVEL AND APPARATUS THEREOF

NºPublicación: EP3294132A1 21/03/2018

Solicitante:
SAMSUNG ELECTRONICS CO LTD [KR]

Resumen de: KR20160133345A

According to an embodiment, disclosed is a blood sugar measuring device. The present invention includes: a glucose detecting part the concentration of glucose in body fluids of a user at a first measurement interval to determine blood sugar content of the user; and a control part changing the first measurement interval to a second measurement interval as an event occurs. The glucose detecting part detects the concentration of glucose in the body fluids at the changed second measurement interval. The control part determines the blood sugar content of the user based on the concentration of the glucose, detected at the changed second measurement interval.



traducir


 

DISTRIBUTED SYSTEM ARCHITECTURE FOR CONTINUOUS GLUCOSE MONITORING

Nº publicación: EP3295343A1 21/03/2018

Solicitante:
DEXCOM INC [US]

Resumen de: WO2016183198A1

The present disclosure relates to techniques for receiving glucose data from a continuous glucose sensor and controlling the use and redistribution of that data so it is used in an intended manner. In one aspect, a method includes preparing data including glucose levels using a continuous glucose sensor unit; wirelessly transmitting the data relating to the glucose levels to a display device from the continuous glucose sensor unit; automatically forwarding the data relating to the glucose levels from the display device to a cloud computing architecture; and storing the data relating to the glucose levels in separate groups at the cloud computing architecture.


traducir



 

previousPage Página2 de 4 nextPage Mostrar por página

Volver